Cost of diabetes mellitus and related macrovascular complications in Turkiye.

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL
Suayip Birinci, Haydar Sur
{"title":"Cost of diabetes mellitus and related macrovascular complications in Turkiye.","authors":"Suayip Birinci,&nbsp;Haydar Sur","doi":"10.14744/nci.2023.24922","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to identify the costs and resources used for diabetes mellitus (DM) and macrovascular complications in Turkiye.</p><p><strong>Methods: </strong>The \"Cost of Illness\" method and a bottom-up costing approach were used in this study. We used e-Nabiz to identify patients with DM and collected their data from 2016 to 2020. We also examined macrovascular complications such as acute coronary syndrome, unstable angina, coronary artery disease, cerebrovascular events, transient ischemic attacks, carotid artery syndrome, intracranial hemorrhage, diabetic foot, heart failure, atrial fibrillation, and peripheral vascular disease using relevant ICD codes. No sampling was done; costs were calculated based on the entire population. When calculating per patient costs, all outpatient/inpatient, medication, intervention, and laboratory/screening tests were considered.</p><p><strong>Results: </strong>Between 2016 and 2020, the e-Nabiz database recorded 7,656,700 people diagnosed with diabetes, a prevalence of 10.4%. The total 2020 cost for treating diabetes was $4,526,212,569 (31,276,128,849 TL), with an average patient cost of $591.145. The health-care expense for 991,945 people diagnosed with major vascular complications due to diabetes was $1,013,004,565.0 (6,999,861,544.16 TL) in 2020, with a per patient average cost also of $591.145 (4048.81 TL). Breakdown of the total cost is 44% for healthcare, 34% for medication, 12% for insulin, 6% for oral antidiabetic drugs, and 1% for testing supplies. Women have a complication rate of 11.2%, while men have a higher rate of 20.8%.</p><p><strong>Conclusion: </strong>DM is both a significant disease burden and an important economic burden. The findings will be a guide the development of effective strategies and sound health policies.</p>","PeriodicalId":19164,"journal":{"name":"Northern Clinics of Istanbul","volume":"10 4","pages":"418-427"},"PeriodicalIF":0.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/af/NCI-10-418.PMC10500234.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Northern Clinics of Istanbul","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/nci.2023.24922","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aimed to identify the costs and resources used for diabetes mellitus (DM) and macrovascular complications in Turkiye.

Methods: The "Cost of Illness" method and a bottom-up costing approach were used in this study. We used e-Nabiz to identify patients with DM and collected their data from 2016 to 2020. We also examined macrovascular complications such as acute coronary syndrome, unstable angina, coronary artery disease, cerebrovascular events, transient ischemic attacks, carotid artery syndrome, intracranial hemorrhage, diabetic foot, heart failure, atrial fibrillation, and peripheral vascular disease using relevant ICD codes. No sampling was done; costs were calculated based on the entire population. When calculating per patient costs, all outpatient/inpatient, medication, intervention, and laboratory/screening tests were considered.

Results: Between 2016 and 2020, the e-Nabiz database recorded 7,656,700 people diagnosed with diabetes, a prevalence of 10.4%. The total 2020 cost for treating diabetes was $4,526,212,569 (31,276,128,849 TL), with an average patient cost of $591.145. The health-care expense for 991,945 people diagnosed with major vascular complications due to diabetes was $1,013,004,565.0 (6,999,861,544.16 TL) in 2020, with a per patient average cost also of $591.145 (4048.81 TL). Breakdown of the total cost is 44% for healthcare, 34% for medication, 12% for insulin, 6% for oral antidiabetic drugs, and 1% for testing supplies. Women have a complication rate of 11.2%, while men have a higher rate of 20.8%.

Conclusion: DM is both a significant disease burden and an important economic burden. The findings will be a guide the development of effective strategies and sound health policies.

Abstract Image

Abstract Image

Abstract Image

土耳其糖尿病及相关大血管并发症的成本。
目的:本研究旨在确定土耳其糖尿病(DM)和大血管并发症的成本和资源。方法:采用“疾病成本法”和自下而上的成本计算方法。我们使用e-Nabiz识别糖尿病患者,并收集他们2016年至2020年的数据。我们还使用相关的ICD代码检查了大血管并发症,如急性冠状动脉综合征、不稳定型心绞痛、冠状动脉疾病、脑血管事件、短暂性脑缺血发作、颈动脉综合征、颅内出血、糖尿病足、心力衰竭、心房颤动和周围血管疾病。没有进行抽样;费用是根据全体人口计算的。在计算每位患者的费用时,考虑了所有门诊/住院、药物、干预和实验室/筛查试验。结果:2016年至2020年,e-Nabiz数据库记录了7,656,700名被诊断患有糖尿病的人,患病率为10.4%。2020年治疗糖尿病的总成本为4,526,212,569美元(31,276,128,849 TL),平均患者成本为591.145美元。2020年,991,945名被诊断患有糖尿病引起的主要血管并发症的人的医疗保健费用为1,013,004,565.0美元(6,999,861,544.16里亚尔),每位患者的平均费用也为591.145美元(4048.81里亚尔)。医疗费用占总费用的44%,药费占34%,胰岛素占12%,口服降糖药占6%,检测用品占1%。女性的并发症发生率为11.2%,而男性的并发症发生率更高,为20.8%。结论:糖尿病既是重要的疾病负担,也是重要的经济负担。调查结果将成为制定有效战略和健全卫生政策的指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Northern Clinics of Istanbul
Northern Clinics of Istanbul MEDICINE, GENERAL & INTERNAL-
CiteScore
0.40
自引率
0.00%
发文量
48
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信